Want to see SE:ACTI full AI Analyst Report?
Top Page
Active Biotech AB
(ACTI)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr3.50
▲(8650.00% Upside)
Action:Reiterated
Date:10/14/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses and cash burn, and declining equity), reinforced by bearish technicals with the price below key moving averages and negative MACD. Valuation offers limited support given the negative P/E and lack of dividend data.
Positive Factors
Very low leverage
Very low debt reduces mandatory financing costs and leaves the company less exposed to refinancing pressure. This provides greater flexibility to allocate available capital toward clinical development and partnerships, although it does not eliminate the need to fund ongoing operating losses.
Negative Factors
No reported revenue
Zero reported revenue means the business has not yet demonstrated commercial monetization of its therapeutic pipeline. Without product, licensing, milestone, or collaboration revenue reflected in the results, future funding remains dependent on advancing assets toward value-creating transactions or eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Very low debt reduces mandatory financing costs and leaves the company less exposed to refinancing pressure. This provides greater flexibility to allocate available capital toward clinical development and partnerships, although it does not eliminate the need to fund ongoing operating losses.
Read all positive factors
Active Biotech AB (ACTI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr85.01M
Dividend YieldN/A
Average Volume (3M)55.26K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue GrowthN/A
EPS Growth54.60%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume57,280
30 Day Avg. Volume55,260
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Active Biotech AB Business Overview & Revenue Model
Company Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, wh...
How the Company Makes Money
Active Biotech AB’s ability to generate revenue is primarily linked to the monetization of its drug development pipeline rather than product sales. Typical revenue sources for a clinical-stage biotech include (1) out-licensing or partnering its dr...
Active Biotech AB Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.60M | -1.60M | -1.64M | -1.68M | -1.49M | -1.28M |
| EBITDA | -32.70M | -36.00M | -38.26M | -43.89M | -56.67M | -48.52M |
| Net Income | -33.60M | -37.30M | -39.40M | -45.80M | -58.69M | -49.88M |
Balance Sheet | ||||||
| Total Assets | 47.90M | 70.20M | 43.20M | 44.05M | 51.01M | 56.80M |
| Cash, Cash Equivalents and Short-Term Investments | 43.90M | 65.10M | 27.40M | 36.22M | 41.80M | 53.13M |
| Total Debt | 100.00K | 1.74M | 3.18M | 4.54M | 6.04M | 986.00K |
| Total Liabilities | 10.70M | 14.60M | 11.13M | 13.38M | 16.49M | 10.13M |
| Stockholders Equity | 37.20M | 55.60M | 32.07M | 30.67M | 34.51M | 46.67M |
Cash Flow | ||||||
| Free Cash Flow | -31.40M | -32.40M | -40.40M | -45.74M | -55.09M | -46.17M |
| Operating Cash Flow | -31.40M | -32.40M | -40.40M | -45.74M | -54.85M | -46.17M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -245.00K | 0.00 |
| Financing Cash Flow | 58.50M | 70.10M | 31.60M | 40.16M | 43.76M | 73.09M |
Active Biotech AB Technical Analysis
Negative
0.04
Price Trends
4.30
Negative
4.94
Negative
5.11
Negative
Market Momentum
-0.33
Negative
24.30
Positive
14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACTI, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 3.55, below the 50-day MA of 4.30, and below the 200-day MA of 5.11, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 24.30 is Positive, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACTI.
Active Biotech AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr377.81M | 1.99 | 63.09% | ― | ― | ― | |
56 Neutral | kr3.89B | -4.78 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr980.37M | -8.85 | -58.12% | ― | ― | 1.42% | |
47 Neutral | kr745.39M | -2.17 | ― | ― | 87.23% | 35.27% | |
43 Neutral | kr85.01M | -8.19 | -93.01% | ― | ― | 54.60% | |
43 Neutral | kr1.42B | -2.72 | -99.58% | ― | -87.22% | -70.29% |
* Healthcare Sector Average
SE:ACTI
Active Biotech AB
3.17
-3.17
-49.99%
SE:HNSA
Hansa Biopharma AB
37.52
4.82
14.74%
SE:BINV
BioInvent International AB
20.50
-7.30
-26.26%
SE:ONCO
Oncopeptides AB
1.66
-3.32
-66.71%
SE:SYNACT
SynAct Pharma AB
17.40
-4.80
-21.62%
SE:CANTA
Cantargia AB
1.37
-1.02
-42.77%
Active Biotech AB Corporate Events
Active Biotech Clears First Safety Cohort in Tasquinimod Myelofibrosis Trial
Oct 13, 2026
Active Biotech has reported that the first cohort of three patients treated under an amended protocol in the European Phase Ib/II HOVON 172 MF study of tasquinimod in myelofibrosis has completed a six-week safety evaluation. One serious adverse ev...
Active Biotech Wins Japanese Patent for Laquinimod Eye Treatment, Bolstering Global IP Strategy
Sep 30, 2026
Active Biotech has secured a key patent in Japan for an ophthalmic eye-drop formulation of its clinical candidate laquinimod, designed to deliver the drug to the posterior parts of the eye for treating severe inflammatory conditions such as non-in...
Active Biotech Deepens U.S. Ties to Advance Tasquinimod in Myelofibrosis
Aug 18, 2026
Active Biotech has expanded its U.S. collaboration by signing a new agreement with the Icahn School of Medicine at Mount Sinai, part of the Myeloproliferative Neoplasms Research Consortium, to support development of its drug candidate tasquinimod ...
Active Biotech Starts Dosing in Amended Tasquinimod Myelofibrosis Trial
Jul 24, 2026
Active Biotech has begun dosing patients in an amended Phase Ib/II clinical study of tasquinimod in myelofibrosis, targeting patients who are refractory to or ineligible for JAK2 inhibitors. The trial, conducted within the HOVON network in the Net...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.